Checkpoint's CK-101 leads to 75% ORR in NSCLC subgroup of Phase I/II

Checkpoint Therapeutics Inc. (NASDAQ:CKPT) said twice-daily 400 mg oral CK-101 (RX518) led to an objective response rate (ORR) of 75% in eight treatment-naïve patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) in a dose-expansion cohort of a Phase I/II trial. Data were presented at the World Conference on Lung Cancer in Toronto.

The company plans to start a Phase III trial next year of CK-101 in treatment-naïve patients with EGFR mutation-positive NSCLC. CK-101 is a third-generation covalent inhibitor of EGFR-activating mutations and the T790M EGFR resistance mutation...